ROME Therapeutics Announces Preclinical Data Demonstrating Inhibition of Endogenous Reverse Transcriptase Activity Blocks Immune Response in Autoimmune Disease Models
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
ROME Therapeutics Expands Science Leadership in Oncology, Data Science and New Target Discovery
ROME Therapeutics announces the appointment of Scott Biller, Ph.D. to its board.
In the news
Over 160 CEOs Sign MassBio’s Pledge to Create a More Equitable and Inclusive Life Sciences Industry| MassBio
Four months after launch, Rome Therapeutics has hired a new chief scientist. Dennis Zaller, Ph.D., arrives at the startup from Celgene, where he spent five years overseeing partnerships with early-stage biotechs across immunology, fibrosis and immuno-oncology and ushering six new drugs into the clinic. | FIERCE Biotech